Agarwal Shefali 4
4 · Epizyme, Inc. · Filed Aug 11, 2022
Insider Transaction Report
Form 4
Epizyme, Inc.EPZM
Agarwal Shefali
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock, par value $0.0001
2022-08-09$1.39/sh+56,527$78,573→ 215,243 total - Exercise/Conversion
Common Stock, par value $0.0001
2022-08-09$1.39/sh+43,473$60,427→ 258,716 total - Exercise/Conversion
Common Stock, par value $0.0001
2022-08-09$1.39/sh+400,000$556,000→ 658,716 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-08-09−43,473→ 400,000 totalExercise: $1.39Exp: 2032-03-16→ Common Stock (43,473 underlying) - Tax Payment
Common Stock, par value $0.0001
2022-08-09$1.39/sh−373,154$518,684→ 285,562 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-08-09−56,527→ 443,473 totalExercise: $1.39Exp: 2032-03-16→ Common Stock (56,527 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-08-09−400,000→ 0 totalExercise: $1.39Exp: 2032-03-16→ Common Stock (400,000 underlying)
Footnotes (2)
- [F1]These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.
- [F2]On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).